Market Overview:
The antibody-mediated rejection market reached a value of US$ 112.3 Million in 2023 and expected to reach US$ 401.8 Million by 2034, exhibiting a growth rate (CAGR) of 12.29% during 2024-2034.
The report offers a comprehensive analysis of the antibody-mediated rejection market in the United States, EU5 (including Germany, Spain, Italy, France, and the United Kingdom), and Japan. It covers aspects such as treatment methods, drugs available in the market, drugs in development, the proportion of various therapies, and the market’s performance in the seven major regions. Additionally, the report evaluates the performance of leading companies and their pharmaceutical products. Current and projected patient numbers across these key markets are also detailed in the report. This study is essential for manufacturers, investors, business planners, researchers, consultants, and anyone interested or involved in the antibody-mediated rejection market.
Request for a Sample of this Report: https://www.imarcgroup.com/antibody-mediated-rejection-market/requestsample
Antibody-Mediated Rejection Market Trends:
Antibody-mediated rejection is a significant complication in organ transplantation, where the immune system of the recipient mounts an attack against the transplanted organ due to the presence of donor-specific antibodies. The antibody-mediated rejection market is propelled by the growing number of organ transplants performed and the increasing awareness of the complexities involved in post-transplant care. Besides this, technological advancements in diagnostic methodologies, such as the development of more sensitive and specific assays for detecting donor-specific antibodies, are driving the expansion of the market.
Additionally, the introduction of novel therapeutic agents aimed at reducing antibody levels or mitigating their effects on the transplanted organ further expands treatment options for patients facing antibody-mediated rejection. Moreover, the evolution of immunosuppressive regimens that better prevent the development of these antibodies while minimizing adverse effects is boosting the growth of the antibody-mediated rejection market. Research efforts focusing on the understanding of the immunological mechanisms underlying antibody-mediated rejection are leading to the identification of new therapeutic targets. Collaborations between academic institutions, healthcare providers, and pharmaceutical companies are facilitating the rapid translation of research findings into clinical practice. As patient survival rates improve with early and accurate diagnosis of antibody-mediated rejection, the demand for effective treatment options is expected to rise, fostering further innovation in the antibody-mediated rejection market.
Countries Covered:
• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country:
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the antibody-mediated rejection market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the antibody-mediated rejection market
• Reimbursement scenario in the market
• In-market and pipeline drugs
This report also provides a detailed analysis of the current antibody-mediated rejection marketed drugs and late-stage pipeline drugs.
In-Market Drugs:
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs:
• Drug overview
• Mechanism of action
• Regulatory status
• Clinical trial results
• Drug uptake and market performance
Competitive Landscape:
The competitive landscape of the antibody-mediated rejection market has been studied in the report with the detailed profiles of the key players operating in the market.
Ask Analyst for Customization and Explore Full Report With TOC & List of Figures: https://www.imarcgroup.com/request?type=report&id=10468&flag=C
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145 | United Kingdom: +44-753-713-2163
